Literature DB >> 18412152

The evolution of resistant Candida species in cancer centers: implications for treatment and prophylaxis.

James Riddell, Carol A Kauffman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18412152     DOI: 10.1002/cncr.23465

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  4 in total

Review 1.  Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole.

Authors:  Kevin Watt; Paolo Manzoni; Michael Cohen-Wolkowiez; Stefano Rizzollo; Elena Boano; Evelyne Jacqz-Aigrain; Daniel K Benjamin
Journal:  Curr Drug Metab       Date:  2013-02       Impact factor: 3.731

2.  Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.

Authors:  Barbara D Alexander; Melissa D Johnson; Christopher D Pfeiffer; Cristina Jiménez-Ortigosa; Jelena Catania; Rachel Booker; Mariana Castanheira; Shawn A Messer; David S Perlin; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

3.  Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.

Authors:  M A Pfaller; S A Messer; R J Hollis; L Boyken; S Tendolkar; J Kroeger; D J Diekema
Journal:  J Clin Microbiol       Date:  2009-08-05       Impact factor: 5.948

4.  Epidemiological Study on Candida Species in Patients with Cancer in the Intensive Care Unit.

Authors:  Young-Ju Choi; Byeongyeo Lee; Sun-A Park
Journal:  Osong Public Health Res Perspect       Date:  2017-12-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.